We have established a hotline for patients and healthcare providers in Ukraine to inform about the availability of our products. We will do our best to provide all necessary information.

  • 0-800-801-341 Toll-Free number in Ukraine
  • 032-246-50-73  Number in Ukraine (charges according to local operator)
  • +48-22-4444911 International number 
  • HOTLINE@novonordisk.com

 

As a pharmaceutical company, it is our responsibility to supply essential medicine to patients with chronic diseases, and we will do all we can to maintain supply in Ukraine and Russia.

With normal supply chains disrupted, we are in dialogue with several international humanitarian organisations to provide relief and have donated medicines and supplies to the Ukrainian Ministry of Health.

 

Although our offices in the besieged capital of Kyiv were shuttered on 24 February, we remain in regular contact with our Ukrainian colleagues – all of whom have been reported safe and unharmed at this time.

We have provided emergency funds to all affected employees to help meet the costs of evacuation. Furthermore, we are coordinating support in neighbouring countries for colleagues and/or their families who wish to leave Ukraine.

 

 

We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.

We have donated up to two months' supply of life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health.

Additionally, the Novo Nordisk Foundation has donated 80 million Danish kroner (approx 10.7m Euro) to support the work of international relief organisations in receiving and assisting refugees, internally displaced people and other vulnerable groups with access to basic necessities such as food and shelter, health and protection

We are in dialogue with several international humanitarian organisations to assess need for product donations. We are looking into different ways we can positively contribute including through our own supply chain capacity and expertise.  

For details, see Frequently Asked Questions below - What is Novo Nordisk doing to support patients in Ukraine that need access to medicines?

We have suspended further marketing and clinical investments in Russia and are focusing our efforts to help our local employees and to ensure more than 700,000 patients can continue their treatment with our essential medication. The factory in Russia is still operating to supply medication to patients in Russia.

In Russia we are pausing starting new clinical trials and halting active enrolment of new patients, where there are currently more than 3,000 patients enrolled. 

We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine.

We have donated up to two months' supply of life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health. We are in dialogue with several international humanitarian organisations to assess need for product donations. We are looking into different ways we can positively contribute including through our own supply chain capacity and expertise.  

On 28 February, the Novo Nordisk Foundation donated 55 million Danish kroner (approx 7.3m Euro) to support the work of international relief organisations in receiving and assisting refugees, internally displaced people and other vulnerable groups with access to basic necessities such as food and shelter, health and protection. This included the 5 million Danish kroner (approx 700K Euro donation announced at the start of the invasion to UNHCR – the UN’s refugee agency - to provide urgent support and protection to people forced to flee their homes.

On 12 April, the Novo Nordisk Foundation provided additional DKK 25 million in support of the emergency response of the World Health Organization (WHO) in Ukraine and neighbouring countries hosting Ukrainian refugees. The support is given based on WHO’s emergency appeal, which addresses the health needs of people in Ukraine and Ukrainian people affected by the conflict in neighbouring countries.

Read more on the Novo Nordisk Foundation's website

We have sufficient stock of medicine in Ukraine across the country, and we have expanded stock of medicines in the neighbouring countries. 

We are doing all we can to maintain the supply of essential medicines to patients living with chronic diseases in Ukraine. We have donated life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health, and we are in dialogue with several international humanitarian organisations to assess need for product donations. 

Our warehouse in Ukraine is still in operation. However, deliveries have been and will be impacted due to shortages in driving staff. We are doing everything we can to get medicines to patients that need them either through pharmacies or humanitarian organizations.

In case the usual supply channels for our medicines get disrupted due to unstable situations in a country, we always aim to partner with local health authorities and humanitarian organisations who have capacity for providing relief on the ground. We are also in dialogue with several international humanitarian organisations to assess the need for product donations. 

We have donated up to two months supply of life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health.

The Novo Nordisk Foundation has donated 55 million Danish kroner (approx 7.3m Euro) to support the work of international relief organisations in receiving and assisting refugees, internally displaced persons and other vulnerable groups with access to basic necessities such as food and shelter, health and protection. This includes a 5 million Danish kroner (approx 700k Euro) donation announced at the start of the invasion to UNHCR – the UN’s refugee agency - to provide urgent support and protection to people forced to flee their homes.

Novo Nordisk has donated life-saving medicine for diabetes and haemophilia from our current stock in Ukraine to the Ministry of Health. We are in dialogue with several international humanitarian organisations to assess need for product donations. We are looking into different ways we can positively contribute, incl. through own supply chain capacity and expertise.  

As a pharmaceutical manufacturer, we are required to follow applicable regulations governing our sales, donations and distribution of medicine. Under these regulations, we can only supply our medicine to entities with the appropriate licence to further sell and/or appropriately distribute our products. In emergency situations, these authorised entities are usually humanitarian organisations with authorisation to provide relief on the ground, or the local health authorities. 

Your Career Guide